Provided by Tiger Fintech (Singapore) Pte. Ltd.

ASCLETIS-B

9.970
+0.2903.00%
Volume:8.29M
Turnover:82.85M
Market Cap:9.90B
PE:-30.37
High:10.150
Open:9.680
Low:9.680
Close:9.680
52wk High:18.750
52wk Low:1.130
Shares:993.00M
HK Float Shares:993.00M
Volume Ratio:1.03
T/O Rate:0.84%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.328
ROE:-12.77%
ROA:-12.32%
PB:4.85
PE(LYR):-30.37
PS:3833.48

Loading ...

Ascletis Pharma Inc - to Issue 28.8 Mln New Shares at HK$16.45 per Share, Others

THOMSON REUTERS
·
Aug 19

Hong Kong Stock Alert | ASCLETIS-B (01672) Rises Over 3% as Interim Shareholder Losses Narrow 32.5% YoY, ASC30 US Phase Ib Study Shows Positive Data

Stock News
·
Aug 18

Stock Track | Ascletis Pharma Soars 5.07% on Promising Weight Loss Drug Combination Results

Stock Track
·
Aug 18

BRIEF-Ascletis Pharma Inc Says Combination Of Asc47 And Asc31 Shows Greater Weight Loss

Reuters
·
Aug 18

ASCLETIS-B (01672): ASC47 Combined with GLP-1R/GIPR Dual Receptor Agonist Peptide ASC31 Demonstrates Superior Weight Loss Effects Compared to ASC47 Plus Tirzepatide Combination in Obese Animal Models

Stock News
·
Aug 18

Ascletis Pharma Inc - Combination of Asc47 and Asc31 Shows Greater Weight Loss

THOMSON REUTERS
·
Aug 18

BRIEF-Ascletis Pharma H1 Net Income RMB -88 Million

Reuters
·
Aug 15

Ascletis Pharma Narrows Loss by 33% in H1

MT Newswires Live
·
Aug 15

ASCLETIS-B (01672) Reports Interim Results with Shareholder Loss of RMB 87.951 Million, Narrowing 32.5% Year-on-Year

Stock News
·
Aug 15

HK Movers | Biotech Shares Soar. PegBio up 35%; Ascletis up 11%; TYK Medicines up 9%

Tiger Newspress
·
Aug 15

BUZZ-Ascletis hits record high on weight loss drug's potential in early trial

Reuters
·
Aug 13

Ascletis' ASC47-Tirzepatide Combo Delivers 87% Greater Weight Loss in Preclinical Study

MT Newswires Live
·
Aug 13

BRIEF-Ascletis Pharma Says ASC47 Showed Greater Efficacy With Tirzepatide

Reuters
·
Aug 13

Ascletis Announces Asc47, a Muscle-Preserving Weight Loss Drug Candidate for Treatment of Obesity, Demonstrated Greater Efficacy With Tirzepatide Than Semaglutide in a Preclinical Model

THOMSON REUTERS
·
Aug 13

Ascletis Pharma Inc - Announces Asc47 Shows Greater Efficacy With Tirzepatide

THOMSON REUTERS
·
Aug 13

Ascletis Pharma Completes Enrollment in Obesity Drug Study in the US

MT Newswires Live
·
Aug 05

HK Movers | Biotech Stocks Extend Rally. Junshi Bio up over 24%; Genor up 23%; Ascletis up 15%; Ascentage up 13%; Dualitybio up 12%

Tiger Newspress
·
Aug 05

Ascletis Announces First Participants With Obesity or Overweight Dosed in Its U.S. 12-Week Phase Iia Study Evaluating Once-Monthly Subcutaneous Depot Formulation of Small Molecule Glp-1R Agonist Asc30

THOMSON REUTERS
·
Jul 28

Ascletis Pharma Inc. Announces Initiation of U.S. Phase IIA Study for Once-Monthly Subcutaneous GLP-1R Agonist ASC30 for Obesity Treatment

Reuters
·
Jul 28

HK Movers | HK's Biotech Shares Soar. Fudan-zhangjiang Soars 22%; Akeso up 11%; CStone Pharma up 9%

Tiger Newspress
·
Jul 17